Related Experiment Videos
An immunotherapeutic vaccine for multibacillary leprosy
1International Centre for Genetic Engineering & Biotechnology, New Delhi, India.
International Reviews of Immunology
|December 30, 1999
Summary
A new leprosy vaccine using Mycobacterium w, administered alongside chemotherapy, accelerates healing and reduces treatment duration. This immunotherapy significantly improves outcomes for non-responsive patients and enhances immune response.
Area of Science:
- Immunology
- Microbiology
- Dermatology
Background:
- Leprosy remains a significant public health challenge, particularly for patients unresponsive to standard multidrug therapy.
- Development of adjunct therapies is crucial to improve treatment efficacy and reduce disease transmission.
Purpose of the Study:
- To review the development and therapeutic application of a novel vaccine for leprosy.
- To evaluate the vaccine's efficacy as an adjunct to chemotherapy in leprosy control.
Main Methods:
- Phase III immunotherapeutic trials were conducted in urban and rural leprosy control centers.
- The study involved patients receiving the Mycobacterium w vaccine in combination with standard chemotherapy.
Main Results:
- The vaccine expedited bacterial clearance and accelerated clinical regression of lesions.
- It significantly shortened the release from treatment (RFT) period for patients.
- The vaccine induced a fall in bacterial index (BI) in non-responders and slow responders, and converted patients to lepromin positivity.
Conclusions:
- The Mycobacterium w vaccine is a safe and effective adjunct to chemotherapy for leprosy.
- It offers significant benefits for patients with persistent disease and enhances cell-mediated immunity.
- The vaccine has received authorization for manufacture and public use in India.